In-hospital medical complications associated with stroke recurrence after initial ischemic stroke

A prospective cohort study from the China National Stroke Registry

Penglian Wang, MD, PhD, Yilong Wang, MD, Xingquan Zhao, MD, Wanliang Du, MD, Anxin Wang, MPH, Galfen Liu, PhD, Liping Liu, MD, Ruijun Ji, MD, Chunxue Wang, MD, Kehui Dong, MD, Yongjun Wang, MD, PhD

Abstract

In-hospital medical complications are common and strongly associated with the risk of death and dependency in stroke patients. Whether similar associations extend to stroke recurrence is unclear. We prospectively and systematically investigated whether in-hospital medical complications are associated with recurrent stroke of patients in the China National Stroke Registry (CNSR). We examined patients with initial ischemic stroke enrolled in CNSR between 2007 and 2008. Recurrent stroke at 3, 6, and 12 months post-stroke was used as stroke outcome. Medical complications were associated with stroke outcomes using multivariable logistic regression.

Of the 7593 study patients, recurrent stroke occurred in 1115 (14.7%) within 12 months after stroke onset. In-hospital medical complications were independent risk factors for stroke recurrence in patients with initial ischemic stroke at 3 months (adjusted odds ratio (OR) = 2.19, 95% confidence interval (CI) 1.85 to 2.60), 6 months (adjusted OR = 2.04, 95% CI 1.74 to 2.38), and 12 months (adjusted OR = 1.88; 95% CI 1.62 to 2.19) after onset. The persistence of secondary prevention medications in patients with complications was lower than that in patients without complications.

Stroke recurrence post-acute ischemic stroke is significantly associated with in-hospital medical complications.

Abbreviations: CI = confidence interval, CNSR = the China National Stroke Registry, IQR = interquartile range, M = month, NIHSS = National Institutes of Health Stroke Scale, OR = odds ratio, SD = standard deviation, TIA = transient ischemic attack.

Keywords: complication, ischemic stroke, outcome, recurrent stroke

1. Introduction

Stroke is a major cause of disability and death worldwide,[1–5] affecting 7 million people each year in China.[6,7] Although initial stroke events play a principal role in the outcome of stroke, recurrent stroke events are relevant to higher mortality rates and disability levels.[6] Given these results, identifying factors that are associated with recurrent stroke is critical. Stroke recurrence is also an important factor in evaluating the quality of health care services. Several studies have identified potential predictors of recurrent stroke, including age,[7–12] race,[11] hypertension,[8,13–17] diabetes mellitus,[7,9,13,17,18] atrial fibrillation,[8,10,14,16] ethanol abuse,[17,19] smoking,[16] hyperlipidemia,[15] elevated homocysteine,[20] patent foramen ovale,[21] and metabolic syndrome.[22] In-hospital medical complications represent potentially modifiable factors contributing to recurrent stroke events. Previous studies have demonstrated that medical complications are strong risk factors for poor outcome in patients with stroke.[19,20] Data from the China National Stroke Registry (CNSR) further confirmed that in-hospital medical complications were independently associated with a greater risk of death or dependency in patients with stroke.[22–24] Despite this evidence, little is known about the association of medical complications with recurrent stroke. We therefore hypothesized that the presence of medical complications during hospitalization predicts stroke recurrence within 12 months after initial ischemic stroke.
2. Methods

2.1. Data collection and study population

The CNSR study is a national, prospective cohort investigation of patient characteristics, risk factors, the stroke care system, and the outcomes of patients with acute stroke in China. Details of the study design have been reviewed previously. Patients with acute stroke were eligible for this prospective registry study if they met the following recruitment criteria: adults of either sex, acute stroke diagnosed using World Health Organization ICD-10 criteria and brain CT or MRI confirmation, patients within the first 14 days after onset of stroke, and written informed consent obtained from patients or surrogate. Patients with initial ischemic stroke were included in this analysis. Enrolled patients who were diagnosed with recurrent ischemic stroke, intracerebral hemorrhage, subarachnoid hemorrhage, or transient ischemic attack (TIA) and refused follow-up were excluded in this analysis. The recruitment period for the CNSR study was between September 2007 and August 2008, and follow-ups were completed in August 2009. We collected data at baseline, at discharge, and at 3, 6, and 12 months after stroke onset. At baseline, every patient was interviewed and evaluated by a trained investigator who recorded demographic information, medical history, family history of stroke, baseline National Institutes of Health Stroke Scale (NIHSS) scores, and other clinical characteristics. The baseline severity of neurological impairment was determined by baseline NIHSS score. During hospitalization, complications, treatments, and other relative information were recorded. Details of secondary prevention medications and other clinical characteristics were recorded at discharge and at 3, 6, and 12 months after patients were recruited. The information was usually obtained from the patient, otherwise the details of the patient were obtained from surrogate or caregiver. Patients were divided into two groups: those with and without in-hospital medical complications.

2.2. Definition of medical complications

All in-hospital medical complications were clarified as non-neurological complications that occurred during the in-hospital period and required an intervention. Pneumonia, urinary tract infection, gastrointestinal bleeding, decubitus ulcer, deep vein thrombosis, and pulmonary embolism were included according to paper-based registry forms. The same criteria were used for diagnosing in-hospital medical complications by all the participating clinical centers to record each medical complication. The in-hospital medical complications were defined as described previously (Supplementary Table 1, http://links.lww.com/MD/B273).

2.3. Ascertainment of outcomes

Recurrent stroke was used as clinical outcome in this analysis. The outcomes of interest were defined as having either a new neurological deficit or a new deterioration of a previous deficit, including ischemic, hemorrhagic, or undetermined stroke (according to WHO criteria) from hospital discharge to 12-month follow-up assessment. Certificates were faxed to Beijing Tiantan Hospital when stroke recurrence was reported by the patient, surrogate, or caregiver during follow-up. A judgement was required for any suspected stroke recurrence by the research coordinators as well as the principal investigator.

2.4. Definition of medication(s) persistence

Persistence to secondary prevention medications was determined for the 3 types of medications: antiplatelet agents (including aspirin or clopidogrel), antihypertensive agents (including calcium-channel blockers, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, or diuretics), and diabetic agents (insulin or oral agents). Standard scripts were used to collect the data on medication(s) persistence. Medication(s) information at discharge after disease onset was considered as the reference value for assessing persistence. Persistence to medications was defined as medication(s) continuation during discharge and 12-month post-onset.

2.5. Statistical analysis

Categorical and continuous variables were respectively expressed as number with proportions, and mean with standard deviation (SD) or median with interquartile range (IQR). Differences between patients with complications and patients without complications were tested by using a t-test for continuous variables and the χ² test for categorical variables. For identifying associations between the patient characteristics and stroke recurrence, univariate logistic regression analyses were performed and presented as unadjusted odds ratios (ORs) with their corresponding 95% confidence intervals (CIs). For identifying associations between in-hospital medical complications and stroke recurrence, univariate logistic regression analyses and multivariate logistic regression analyses were performed and presented as adjusted ORs with their corresponding 95% CIs and adjusted ORs with the 95% CIs. Adjusted potential covariates included age, sex, baseline NIHSS, hypertension, diabetes mellitus, hyperlipidemia, history of coronary heart disease, family history of stroke, atrial fibrillation, current smoking status, dysphagia, heavy alcohol intake, anticoagulant treatment, thrombolytic treatment, and types of health insurance. Missing values are treated as the most categories or the categories based on clinical perspective. SAS statistical software, version 9.4 (SAS Institute Inc., Cary, NC) was used to analyze data, considering statistical significance by a two-tailed probability value of <0.05.

2.6. Standard protocol approvals and patient consents

The study design and procedures were approved by the institutional review in each participating hospital before screening subjects for CNSR. Written informed consent was obtained from all patients or surrogates of patients recruited in the study.

3. Results

Overall, 22,216 hospitalized patients with stroke from 132 sites were enrolled in the CNSR study. Of these, 18,580 stroke patients agreed to participate in the follow-up studies following their first visit, of which there were 12,413 patients with ischemic stroke. We excluded 4234 individuals with recurrent stroke and 588 individuals missing follow-up data, leaving 7593 participants with initial ischemic stroke in the final analysis (Fig. 1). The prevalence of pneumonia, urinary tract infection, gastrointestinal bleeding, decubitus ulcer, deep vein thrombosis, and pulmonary embolism during hospital was 10.6%, 3.2%, 2.2%, 0.5%, 0.4%, and 0.3%, respectively. Of 7593 patients, 1061 (13.9%) patients had an in-hospital medical complication(s).
We reported the baseline characteristics of participants having initial ischemic stroke without or with in-hospital medical complications (Table 1). The median age was 64, and 61.4% were male. In general, compared with participants without in-hospital medical complications, participants with complications were significantly more likely to be older; to have a history of coronary heart disease, atrial fibrillation, and higher NIHSS scores; and to be receiving anticoagulants or thrombolytic treatment. Participants with complications were less likely to have diabetes mellitus and a family history of stroke. There were no significant differences in the proportion of hypertension, hyperlipidemia, history of TIA, and types of health insurance for participants with or without complications.

The clinical outcomes of this study at 3, 6, and 12 months after stroke are shown in Fig. 2. The rate of recurrent stroke at 3, 6, and 12 months after initial ischemic stroke was 10.9% (824 patients), 13.4% (1019 patients), and 14.7% (1115 patients), respectively. The rate of recurrent stroke was significantly higher in participants with complications than that in patients without complications at all-time points (Fig. 2). The univariate logistic regression analysis showed that age, diabetes mellitus, coronary heart disease, atrial fibrillation, history of TIA, having anticoagulants, having thrombolytic treatment, baseline NIHSS, and types of health insurance were significantly associated with recurrent stroke at 3, 6, or/and 12 months after stroke (Table 2). In-hospital medical complications were associated with greater risk of recurrent stroke events in analyses adjusted for age, sex, baseline NIHSS, hypertension, diabetes mellitus, hyperlipidemia, history of coronary heart disease, history of TIA, family history of stroke, atrial fibrillation, current smoking status, dysphagia, heavy alcohol intake, anticoagulant treatment, thrombolytic treatment, and types of health insurance (Fig. 3). The adjusted ORs of recurrent stroke were approximately 2.2-fold, 2.0-fold, and

| Table 1 | Baseline characteristics of patients with initial ischemic stroke (N = 7593). |
|---------|---------------------------------------------------------------|
| Variable | Total (N = 7593) | Without medical complications (n = 6532) | With medical complications (n = 1061) | P |
| Age, mean ± SD, y | 64 ± 13 | 63 ± 13 | 70 ± 12 | <0.001 |
| Age category, n (%) | | | | |
| <65 years | 3657 (48.2) | 3372 (51.6) | 285 (26.9) | <0.001 |
| ≥65 years | 3936 (51.8) | 3160 (48.4) | 776 (73.1) | <0.001 |
| Male, n (%) | 4660 (61.4) | 4114 (63.0) | 546 (51.5) | <0.001 |
| Hypertension, n (%) | 4363 (57.5) | 3756 (57.5) | 607 (57.2) | 0.859 |
| Hyperlipidemia, n (%) | 674 (8.9) | 592 (9.1) | 82 (7.7) | 0.156 |
| Diabetes mellitus, n (%) | 1267 (16.7) | 1123 (17.2) | 144 (13.6) | 0.003 |
| Coronary heart disease, n (%) | 957 (12.6) | 759 (11.6) | 198 (18.7) | <0.001 |
| Atrial fibrillation, n (%) | 772 (10.2) | 406 (6.6) | 276 (26.0) | <0.001 |
| History of TIA, n (%) | 189 (2.5) | 169 (2.6) | 20 (1.9) | 0.173 |
| Family history of stroke, n (%) | 874 (11.5) | 786 (12.0) | 88 (8.3) | <0.001 |
| Anticoagulant treatment, n (%) | 1803 (23.7) | 1498 (22.9) | 305 (28.7) | <0.001 |
| Thrombolytic treatment, n (%) | 298 (3.9) | 243 (3.7) | 55 (5.2) | 0.023 |
| Baseline NIHSS, median (IQR) | 5.0 (2.0–9.0) | 4.0 (2.0–8.0) | 11.0 (5.0–18.0) | <0.001 |
| Types of health insurance | | | | 0.757 |
| GHI | 5775 (76.1) | 4970 (76.1) | 805 (75.9) | |
| Commercial | 244 (3.2) | 205 (3.1) | 39 (3.7) | |
| Self-payment | 1574 (20.7) | 1357 (20.8) | 217 (20.4) | |

GHI = government health insurance, IQR = interquartile range, NIHSS = National Institutes of Health Stroke Scale, SD = standard deviation, TIA = transient ischemic attack.
1.9-fold greater in participants with complications when compared with those without complications at 3, 6, and 12 months, respectively.

To evaluate possible explanations for the effect of in-hospital medical complication on stroke recurrence after acute ischemic stroke, we compared differences of patients with or without in-hospital medical complications in the persistence for secondary prevention associated with stroke recurrence (Table 3). By medication class, 12-month persistence was highest for antihypertensive agents (72.7%), followed by diabetic (66.2%), and antiplatelet (54.9%) agents (Table 3). Patients with in-hospital medical complications were less likely to have persistence of antihypertensive, diabetic, and antiplatelet agents than patients without in-hospital medical complications within 12 months after disease onset.

4. Discussion

The CNSR was a prospective stroke registry that enrolled maximal numbers of stroke patients from the most areas in China so far. In the present study, patients with initial acute ischemic stroke from the CNSR were selected, and the impact of in-hospital medical complications on stroke recurrence was analyzed. In this national prospective cohort, in-hospital medical complications were associated with a higher risk of stroke recurrence in participants with initial ischemic stroke within 12 months after the event. This finding confirms that stroke recurrence in ischemic stroke patients is affected by in-hospital medical complications.

A substantial body of evidence suggests that stroke patients are more susceptible to medical complications and their consequen-
ces, such as an increased risk of death or disability.\cite{24-26,29,36-39} Prior studies on the effect of medical complications on stroke outcome mainly focused on death and disability.\cite{31-33} In a recent analysis from the Berlin Stroke Registry study, an effect of acute complications on mortality in ischemic stroke patients was observed, such that the risk of death was 2.5-times higher in participants with in-hospital complications when compared with those without complications.\cite{37} Similarly, we previously showed that the risk of death was significantly higher in stroke patients with in-hospital medical complications than in those without complications, even after adjusting for traditional cerebrovascular risk factors, baseline severity of neurological impairment, anticoagulant treatment, and thrombolytic treatment.\cite{38} Moreover, limited studies aiming at the impact of complications on stroke outcomes demonstrated that patients with complications experienced a higher risk of dependency after stroke than those without complications.\cite{13,39,40} The results of the current study extend these findings by showing that in-hospital medical complications confer an approximately 2-times greater risk of stroke recurrence at 3 months after disease onset, and the risks of recurrent stroke associated with in-hospital medical complications have similar tendencies at 6 months and 12 months after stroke onset. These data suggest that stroke patients with in-hospital medical complications have greater susceptibility to stroke recurrence than those without in-hospital medical complications, which, in turn, may account for much of their excess risk of stroke recurrent events. The reasons why in-hospital medical complications are associated with mortality and disability after stroke onset may be explained by the impact of hospital stays on worsening brain injury, elevated opportunity for recurrent complications, and decreased chance of appropriate post-stroke rehabilitation. The mechanism by which in-hospital medical complications are associated with recurrent stroke is unclear.

Previous studies have found that age,\cite{7-12} race,\cite{10} hypertension,\cite{18,19,20} diabetes mellitus,\cite{7,9,13,17,18,21} atrial fibrillation,\cite{16,10,14,15} elevated homocysteine,\cite{11} ethanol abuse,\cite{19} smoking,\cite{16} hyperlipidaemia,\cite{11} elevated homocysteine,\cite{19} patent foramen ovale,\cite{21} and metabolic syndrome\cite{22} predict stroke recurrence. Acupuncture also might play a role in decreasing recurrent stroke events even in ischemic stroke.\cite{41} Medical complications may mediate these predictors of stroke recurrence in patients although the frequency of complications varied widely in the previous studies for various reasons, such as, having the different definitions and types of complications, the varied period for evaluating complications, the different stroke types, and different sample sizes and demographics between studies.\cite{24-27,32,37,38,40} Furthermore, antithrombotic treatments are recommended for secondary prevention after stroke caused by presumed arterial origin, decreasing the risk of recurrent stroke.\cite{42-47} A previous meta-analysis also showed that the risk of recurrent stroke was significantly lower in participants with antihypertensive drugs than those without antihypertensive drugs.\cite{48} Additionally, our previous study confirmed that the risk of stroke recurrence was increased by diabetes.\cite{18} Given that secondary prevention is an important measure to reduce stroke recurrence in stroke patients, a conceivable explanation for our findings is that in-hospital complications may confer a decreased compliance with secondary prevention in participants. Supporting this possibility is the finding that differences in the compliance with secondary prevention were observed between participants with and without in-hospital medical complications. Following stroke onset, participants without complications are more likely to persist in secondary preventive therapies such as aspirin and antihypertensive treatment and antidiabetic treatment, which perhaps partly aggravate differences in the risk for recurrent stroke events. Thus, these factors should be weighed for stroke patients with complications in order to investigate further the mechanisms of stroke recurrence associated with complications and to give proper secondary prevention treatment.

The AVAIL study investigated first the potential factors that were associated with persistence to secondary prevention following stroke.\cite{49} According to the AVAIL study, having insurance to cover medication costs increased by 60% the odds of adherence, which decreased the risk of recurrent stroke. This study also extended the finding that an increased risk of stroke recurrence was associated with no health insurance in patients with initial ischemic stroke before adjusted potential covariates. However, the interesting point of this prospective study was that the risk of stroke recurrence was increased by complications even after adjusted potential covariates, including types of health insurance. In addition, the ratio of having different types of health insurance for patients with complications was similar to that for those without complications in this study. Therefore, this result

### Table 3

**Persistence for secondary prevention medications within 12 months after stroke onset.**

| Variable          | Total (N = 7593) | Without medical complications (n = 6532) | With medical complications (n = 1061) | P  |
|-------------------|------------------|----------------------------------------|-------------------------------------|----|
| Antiplalet agents |                  |                                        |                                     |    |
| At discharge, n   | 5621             | 5034                                   | 587                                 |    |
| Persistence at 3M | 83.6%            | 85.0%                                  | 71.4%                               | <0.001 |
| Persistence at 6M | 79.6%            | 81.2%                                  | 65.4%                               | <0.001 |
| Persistence at 12M| 54.9%            | 56.7%                                  | 39.5%                               | <0.001 |
| Antihypertensive agents |           |                                        |                                     |    |
| At discharge, n   | 3676             | 3163                                   | 513                                 |    |
| Persistence at 3M | 76.3%            | 79.3%                                  | 57.9%                               | <0.001 |
| Persistence at 6M | 80.8%            | 84.9%                                  | 55.6%                               | <0.001 |
| Persistence at 12M| 72.7%            | 77.1%                                  | 44.9%                               | <0.001 |
| Diabetic agents   |                  |                                        |                                     |    |
| At discharge, n   | 1267             | 1123                                   | 144                                 |    |
| Persistence at 3M | 96.7%            | 96.6%                                  | 97.2%                               | 0.058  |
| Persistence at 6M | 96.4%            | 97.0%                                  | 91.7%                               | <0.001 |
| Persistence at 12M| 66.2%            | 67.3%                                  | 57.6%                               | <0.001 |

At discharge, n = 7593, Persistence at 3M = 6532, Persistence at 6M = 513, Persistence at 12M = 39, P = 0.001.

M = months.
emphasizes the necessity and importance of specific programs aimed at investigating the mechanisms that underlie complications affecting stroke recurrence in China.

In addition, the different medical complications had different effects on stroke recurrence (Supplementary Table 2, http://links.lww.com/MD/B273). In particular, inflammation may play an important role in stroke recurrence according to our data. Furthermore, we are limited in our current knowledge as to whether effective prevention and treatment of such in-hospital complications can abolish their adverse effects on ischemic stroke recurrence. Therefore, the mechanisms of stroke recurrence associated with in-hospital medical complications need to be further investigated to ascertain these issues.

There are some limitations to this prospective study. This study only included 6 types of complications, and the definitions of some complications were relatively simple. However, all participating hospitals did use the same criteria for diagnosing in-hospital medical complications, and the reported uncertain cases with complications were few. We analyzed data based on a diagnosis of medical complication during hospitalization and did not include information about treatment for medical complications that may be associated with stroke recurrence. In addition, data on newly occurring medical complications were not included during the follow-up period. Thus, we could not address the effects of new medical complications during follow-up on stroke recurrence of patients. This present study did not include whether adequate target levels for blood pressure and glucose had been achieved nor did it collect reasons for medication discontinuation. In addition, information about psychological and cognitive functions after acute stroke was not collected in this study, which may affect behaviors of taking medication(s). Finally, the CNSR study may not represent all levels of hospital expertise because all participating hospitals were from urban regions across China, where investigators may have had more expertise in treating stroke and better medical care resources.

In conclusion, in-hospital medical complications were found to be significantly associated with stroke recurrence after acute ischemic stroke. The decreased adherence to stroke secondary prevention in participants with complications may indirectly cause the elevated events of stroke recurrence. Therefore, future studies aimed at decreasing the rates of stroke recurrence should consider the prevention and treatment of medical complications after stroke. Programs on stroke recurrence need to investigate potential variations carefully, including the impact of adherence to preventive interventions for secondary stroke.

Acknowledgments
The authors would like to thank the patients who participated in this CNSR study and all investigators, nurses, and imaging and laboratory staff in all participating centers, as well as the details of the study design which have been published previously.134

References
[1] Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation 2016;133:e38–60.
[2] Liu M, Wu H, Wang WZ, et al. Stroke in China: epidemiology, prevention, and management strategies. Lancet Neurol 2007;6: 456–64.
[3] Johnston SC, Mendis S, Mathers CD. Global variation in stroke burden and mortality: estimates from monitoring, surveillance, and modelling. Lancet Neurol 2009;8:345–54.
[4] Towfighi A, Saver JL. Stroke declines from third to fourth leading cause of death in the United States: historical perspective and challenges ahead. Stroke 2011;42:2351–5.
[5] Mozaffarian D, Benjamin EJ, Go AS, et al. Executive summary: heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation 2016;133:447–54.
[6] Samsa GP, Rian J, Lipcomb J, et al. Epidemiology of recurrent cerebral infarction: a medicare claims-based comparison of first and recurrent strokes on 2-year survival and cost. Stroke 1999;30:338–49.
[7] Hankey GJ, Jamrozik K, Broadhurst RJ, et al. Long-term risk of first recurrent stroke in the Perth Community Stroke Study. Stroke 1998;29:2491–500.
[8] Mohan KM, Crichton SL, Grieve AP, et al. Frequency and predictors for the risk of stroke recurrence up to 10 years after stroke: the South London Stroke Register. J Neurol Neurosurg Psychiatry 2009;80:1012–8.
[9] Petty GW, Brown RD Jr, Whisnant JP, et al. Survival and recurrence after first cerebral infarction: a population-based study in Rochester, Minnesota, 1975 through 1989. Neurology 1998;50:208–16.
[10] Modregø PJ, Mainar R, Turull R. Recurrence and survival after first-ever stroke in the area of Bajo Aragon, Spain. A prospective cohort study. J Neurol Sci 2004;224:49–55.
[11] Feng W, Hendry RM, Adams RJ. Risk of recurrent stroke, myocardial infarction, or death in hospitalized stroke patients. Neurology 2010;74:388–93.
[12] Kuwashiro T, Sugimori H, Ago T, et al. FSR Investigators. Risk factors predisposing to stroke recurrence within one year of non-cardioembolic stroke onset: the Fukushima Stroke Registry. Cerebrovasc Dis 2012;33:141–9.
[13] Hier DB, Foulke MA, Swiontkowski M, et al. Stroke recurrence within 2 years after ischemic infarction. Stroke 1999;30:155–61.
[14] Lai SM, Alter M, Friday G, et al. A multifactorial analysis of risk factors for recurrence of ischemic stroke. Stroke 1994;25:938–62.
[15] Loo T, Lindingen A, Persson J, et al. Risk factors and treatment at recurrent stroke onset: results from the Recurrent Stroke Quality and Epidemiology (RESQUE) Study. Cerebrovasc Dis 2008;25:254–60.
[16] Xu G, Liu X, Wu W, et al. Recurrence after ischemic stroke in Chinese patients: impact of uncontrolled modifiable risk factors. Cerebrovasc Dis 2007;23:117–20.
[17] Sacco RL, Shi T, Zamanillo MC, et al. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Stroke Study. Neurology 1994;44:626–34.
[18] Jia Q, Zhao X, Wang C, et al. Diabetes and poor outcomes within 6 months after acute ischemic stroke: the China National Stroke Registry. Stroke 2011;42:2758–62.
[19] Ois A, Gomis M, Rodriguez-Campello A, et al. Factors associated with a high risk of recurrence in patients with transient ischemic attack or minor stroke. Stroke 2008;39:1717–21.
[20] Boysen G, Brandt T, Christensen H, et al. Incidence of stroke during follow-up after large-vessel infarction. Eur J Neurol 2008;15:802–9.
[21] Shah SV, Corrado G, Bergman D, et al. Impact of poststroke medical complications on 30-day readmission rate. J Stroke Cerebrovasc Dis 2015;24:1969–77.
[22] Johnston KC, Li JY, Lyden PD, et al. Medical and neurological complications of ischemic stroke: experience from the RANNTAS trial. RANNTAS Investigators. Stroke 1998;29:447–53.
[23] Langhorne P, Stott DJ, Robertson L, et al. Medical complications after stroke: a multicenter study. Stroke 2000;31:1223–9.
[24] Bae HJ, Yoon DS, Lee J, et al. In-hospital medical complications and long-term mortality after ischemic stroke. Stroke 2005;36:2441–5.
[25] Grube MM, Koenecke HC, Walter G, et al. Influence of acute complications on outcome 3 months after ischemic stroke. PLoS One 2013;8:e75719.
[26] He Q, Wu C, Luo H, et al. Trends in in-hospital mortality among patients with stroke in China. PLoS One 2014;9:e92763.
[27] Heuschmann PU, Kolominsky-Rabas PL, Misselwitz B, et al. Predictors of in-hospital mortality and preventable risks of death after ischemic stroke: the German Stroke Registers Study Group. Arch Intern Med 2004;164:1761–8.
[28] Saposnik G, Hill MD, O’Donnell M, et al. Variables associated with 7-day, 30-day, and 1-year fatality after ischemic stroke. Stroke 2008;39: 2318–24.
[31] Vernino S, Brown RD Jr, Sejvar JJ, et al. Cause-specific mortality after first cerebral infarction: a population-based study. Stroke 2003;34:1828–32.
[32] Wang PL, Zhao XQ, Yang ZH, et al. Effect of in-hospital medical complications on case-fatality post-acute ischemic stroke: data from the China National Stroke Registry. Chin Med J (Engl) 2012;125:2449–54.
[33] Wang PL, Zhao XQ, Du WL, et al. In-hospital medical complications associated with patient dependency after acute ischemic stroke: data from the China National Stroke Registry. Chin Med J (Engl) 2013;126:1236–41.
[34] Wang Y, Cui L, Ji X, et al. The China National Stroke Registry for patients with acute cerebrovascular events: design, rationale, and baseline patient characteristics. Int J Stroke 2011;6:355–61.
[35] Brott T, Adams HP Jr, Olinger CP, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989;20:864–70.
[36] Lavados PM, Sacks C, Prina L, et al. Incidence, 30-day case-fatality rate, and prognosis of stroke in Iquique, Chile: a 2-year community-based prospective study (PISCIS project). Lancet 2005;365:2206–15.
[37] Davenport RJ, Dennis MS, Wellwood I, et al. Complications after acute stroke. Stroke 1996;27:415–20.
[38] Hong KS, Kang DW, Koo JS, et al. Impact of neurological and medical complications on 3-month outcomes in acute ischaemic stroke. Eur J Neurol 2008;15:1324–31.
[39] Ogata T, Kamouchi M, Matsuo R, et al. Gastrointestinal bleeding in acute ischemic stroke: recent trends from the fukuoka stroke registry. Cerebrovasc Dis Extra 2014;4:156–64.
[40] Pandian JD, Kaur A, Jyotsna R, et al. Complications in acute stroke in India (CAST-I): a multicenter study. J Stroke Cerebrovasc Dis 2012;21:695–703.
[41] Shih CC, Liao CC, Sun MF, et al. A retrospective cohort study comparing stroke recurrence rate in ischemic stroke patients with and without acupuncture treatment. Medicine (Baltimore) 2015;94:e1572.
[42] Adams RJ, Albers G, Alberts MJ, et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2008;39:1647–52.
[43] European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008;25:457–507.
[44] Wang YJ, Zhang SM, Zhang L, et al. Chinese guidelines for the secondary prevention of ischemic stroke and transient ischemic attack 2010. CNS Neurosci Ther 2012;18:93–101.
[45] Yip S, Benavente O. Antiplatelet agents for stroke prevention. Neurotherapeutics 2011;8:475–87.
[46] Malloy RJ, Kanaan AO, Silva MA, et al. Evaluation of antiplatelet agents for secondary prevention of stroke using mixed treatment comparison meta-analysis. Clin Ther 2013;35:1490.e7–500.e7.
[47] Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013;369:11–9.
[48] Rashid P, Leonard-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke 2003;34:2741–8.
[49] Bushnell CD, Olson DM, Zhao X, et al. Secondary preventive medication persistence and adherence 1 year after stroke. Neurology 2011;77:1182–90.